another record low share price realised, and under the $2 floor, which will likely now become the ceiling given how poorly this company is managed. It looks like the market believes that the only thing Anaconda pharma has to offer is Disallowed.
And the US management is proving that the only thing they are good at is following in the footsteps.of Australian managememt.
This has been an absolutely disastrous investment choice.....
- Forums
- ASX - By Stock
- BTA
- Ozbiota Blogspot
Ozbiota Blogspot, page-10
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)